Abstracts Archive - Page 108 of 2607 - ACR Meeting Abstracts

Abstract Number: 1234 • ACR Convergence 2025
Serum Antibodies Against Glial Fibrillary Acidic Protein in Fibromyalgia: A Proof-of-Concept Study
Felipe Massó¹, Laura Aline Martinez-Martinez², Luis M Amezcua-Guerra³, Francisco Mercado⁴, Angélica Almanza⁵ and Manuel Martínez-Lavín¹, ¹Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ²Rheumatology Department at National Institute of Cardiology Ignacio Chávez, Mexico City, Federal District, Mexico, ³Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico city, ⁴Instituto Nacional de Psiquiatría Ramón del la Fuente Muñiz, Mexico city, Mexico, ⁵Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico city, Mexico
Background/Purpose: Fibromyalgia (FM) is a stress-related disorder in which dorsal root ganglia (DRG) may play a pivotal pathogenetic role. DRG exhibit unique stress-induced, pro-algesic physio-anatomy,…
Abstract Number: 1134 • ACR Convergence 2025
Efficacy and Safety of Anakinra for Acute Calcium Pyrophosphate Deposition Disease Flare: A Systematic Review and Meta-Analysis
Pannathorn Nakaphan¹, Somkiat Phutinart², Patavee Pajareya², Priabprat Jansem³, Nattanicha Chaisrimaneepan⁴, Pim Jetanalin⁵ and Noppachai Siranart², ¹Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, ²Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ³Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand, ⁴Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ⁵Department of Medicine, Division of Rheumatology, University of Illinois College of Medicine, Chicago, IL
Background/Purpose: Calcium Pyrophosphate Deposition Disease (CPPD) is a common inflammatory arthritis among older adults. Comorbidities often limit conventional treatment of acute CPPD flare. Anakinra, an…
Abstract Number: 1207 • ACR Convergence 2025
Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis
Jesus Valencia¹, Will Kelly¹, Sean Tackett², Amanda Finney¹, Jemima Albayda¹, Julie Paik³, Lisa Christopher-Stine¹ and Chris Mecoli⁴, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease characterized by cutaneous manifestations and proximal muscle inflammation.1,2 Notably, the clinical course of muscular and cutaneous disease…
Abstract Number: 1175 • ACR Convergence 2025
Secukinumab In Patients with Giant Cell Arteritis with Polymyalgia Rheumatica Symptoms: A Post Hoc Analysis of the Phase 2 TitAIN Study
Nils Venhoff¹, Wolfgang Schmidt², Raoul Bergner³, Juergen Rech⁴, Leonore Unger⁵, Stephanie Finzel⁶, Ioana Andreica⁷, David Kofler⁸, Stefan Weiner⁹, Prof. Dr. med. Peter Lamprecht¹⁰, Hendrik Schulze-Koops¹¹, Meryl Mendelson¹², Weibin Bao¹³, Monica Keyport¹⁴, Meron Maricos¹⁵, Valeria Jordan M.¹⁶ and Jens Thiel¹⁷, ¹University of Freiburg, Freiburg, Germany, ²Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany, ³Department of Internal Medicine A, Nephrology and Rheumatology, Municipal Hospital Ludwigshafen, Ludwigshafen, Germany, ⁴Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁵Städtisches Klinikum Dresden, Dresden, Germany, ⁶Universitétsklinikum Freiburg, Freiburg im Breisgau, Germany, ⁷Rheumazentrum Ruhrgebiet Herne; Ruhr-Universität Bochum, Germany, Herne, Germany, ⁸University of Cologne, Cologne, Germany, ⁹Brüderkrankenhaus Trier, Trier, Germany, ¹⁰University of Lübeck, Lübeck, Germany, ¹¹LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany, ¹²Novartis Pharmaceuticals, Larchmont, NY, ¹³Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁴Novartis Pharmaceuticals, Stillwater, MN, ¹⁵Novartis, Nürnberg, Germany, ¹⁶Novartis Pharmaceuticals Corporation, Tenafly, NJ, ¹⁷University Hospital Freiburg, Medical University Graz, Freiburg, Germany
Background/Purpose: GCA and PMR are closely related, immune-mediated chronic inflammatory diseases often occurring concurrently in individuals over 50.1,2 While glucocorticoids (GC) are the mainstay of…
Abstract Number: 1162 • ACR Convergence 2025
Antineutrophil cytoplasmic antibody-associated isolated interstitial lung disease
Javier Narváez¹, Pol Maymó-Paituvi², Vanesa Vicens Zygmunt³, Guadalupe Bermudo⁴, Martí Aguilar-Coll⁵, Montserrat Roig Kim², Laia De Daniel Bisbe², Joan Miquel Nolla² and Maria Molina-Molina⁴, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ³Interstitial Lung Disease Unit. Department of Pneumology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Interstitial Lung Disease Unit. Department of Pneumology. Hospital Universitario de Bellvitge., Barcelona, Spain, ⁵Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: There is increasing evidence of the association between interstitial lung disease (ILD) and ANCA positivity without other manifestations of systemic vasculitis. The prognosis of…
Abstract Number: 1172 • ACR Convergence 2025
A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients with IgG4-Related Disease
Matthew Charles Baker¹, Audra Horomanski², Robert Fairchild³, Yuhan Liu³, Mariani Diaz Deluna³, Tobias Lanz⁴, Saurabh Gawde³, Mehdi Khalighi³, Benjamin Franc³, Mrudula Penta³, Nancy Pham³ and Kip Guja³, ¹Stanford University, Menlo Park, CA, ²Stanford University, Palo Alto, CA, ³Stanford University, Stanford, CA, ⁴Stanford University, Stanford
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic, systemic, immune-mediated disease that is commonly treated with B cell depletion. However, due to potential risks associated with…
Abstract Number: 1227 • ACR Convergence 2025
The Composition of Circulating Immune Cells is Associated with Nociplastic Pain in Patients with Rheumatoid Arthritis
Tyler Therron¹, Meghan Mayer², Cecilia Stumpf³, Gelis Galarcé Lugo⁴, Morgan Langereis⁵, Kathleen Aren⁶, Mary Carns⁵, Cally Mills⁵, Cheol Min Lee⁷, Vanessa Manada De Lobos², Carla Marie Cuda⁵, Yvonne Lee⁵ and Deborah Rachelle Winter⁸, ¹Northwestern Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University, Elmhurst, IL, ⁴Northwestern University Feinberg School of Medicine, Zionsville, IN, ⁵Northwestern University, Chicago, IL, ⁶Northwestern University Division of Rheumatology, Chicago, IL, ⁷Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Northwestern University, Skokie, IL
Background/Purpose: Over half of patients with RA report clinically meaningful pain, despite treatment with disease-modifying antirheumatic drugs (DMARDs). While joint inflammation is a known cause…
Abstract Number: 1127 • ACR Convergence 2025
The Pathogenetic Role of Calcium Pyrophosphate and Basic Calcium Phosphate Crystals in Osteoarthritis: Associations with Synovial Fluid Cytokines and Clinical Indices
Francesca Oliviero¹, Chiara Baggio², Amelia Damasco², Federico Zorzi³, Mariagrazia Lorenzin², Giacomo Cozzi² and Roberta Ramonda⁴, ¹Rheumatology Unit, Department od Medicine - DIMED, University of Padova, Padova, Veneto, Italy, ²Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Veneto, Italy, ³Center for Analysis and Certification Services (CEASC), University of Padova, Padova, Veneto, Italy, ⁴Rheumatology Unit-DIMED-University of Padova ITALY, Padova, Padua, Italy
Background/Purpose: Calcium pyrophosphate (CPP) and basic calcium phosphate (BCP) crystals are frequent features of synovial fluid (SF) in patients with osteoarthritis (OA). Although these crystals…
Abstract Number: 1215 • ACR Convergence 2025
Remission Rates and Predictors in Idiopathic Inflammatory Myopathy Subtypes: Insights from a Single-Center Cohort
Nantakarn Pongtarakulpanit¹, Sidra Tahir², Varshapriya Suresh², Vaidehi Kothari³, Shiri Keret⁴, Eugenia Gkiaouraki⁵, Siamak Moghadam-Kia⁶, Vladimir Liarski⁷, Dana Ascherman⁵ and Rohit Aggarwal⁸, ¹Mahidol University, University of Pittsburgh, Bangkok, Thailand, ²Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ³University of Pittsburgh Medical Center, Pittsburgh, ⁴Bnai Zion Medical Center, Atlit, Israel, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷University of Pittsburgh School of Medicine, Pittsburgh, ⁸University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: With therapeutic advances in idiopathic inflammatory myopathy (IIM), achieving remission has become an important goal. However, comprehensive data on remission, particularly across IIM subtypes,…
Abstract Number: 1007 • ACR Convergence 2025
Accelerometry-Derived Activity and Sleep Patterns in the NIH All of Us Cohort: Insights and Predictive Potential for Inflammatory Arthritis
adeep Kulkarni¹, Jose Scher², Rebecca Haberman³ and Souptik Barua¹, ¹New York University Grossman School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Langone Health, New York, NY
Background/Purpose: Patients with inflammatory arthritis (IA) report reduced physical activity and poor sleep, However, much remains unknown about the extent and impact of this relationship.…
Abstract Number: 1150 • ACR Convergence 2025
Impact of IL-17A on synovial fibroblast from subacromial bursae
Andre Ramon¹, Hélène Greigert², baptiste lamarthée³, Corentin Richard⁴, claudie Cladière³, Noemie Klopfenstein³, Ludovic Labattut⁵, Alice Bordet⁵, Sylvain Audia⁶, Romain boidot⁴, jean-francis Maillefert¹, Bernard Bonnotte⁷ and Maxime Samson⁸, ¹Rheumatology, Université Bourgogne Europe, CHU Dijon Bourgogne, Dijon, France, ²Vascular Medicine, Université Bourgogne Europe, CHU Dijon Bourgogne, Dijon, France, ³Marie et Louis Pasteur University, EFS, INSERM, UMR RIGHT, Besançon, France, Dijon, France, ⁴Molecular Biology Unit, Georges-François Leclerc Cancer Center, UNICANCER, Dijon, France, Dijon, France, ⁵Orthopedic Surgery, Université Bourgogne Europe, CHU Dijon Bourgogne, Dijon, France, ⁶Internal Medicine and Clinical Immunology, Université Bourgogne Europe, CHU Dijon Bourgogne, Dijon, France, ⁷Internal medicine and clinical immunology, Université Bourgogne Europe , CHU Dijon Bourgogne, Dijon, France, ⁸CHU Dijon Bourgogne, Dijon, France
Background/Purpose: Polymyalgia rheumatica (PMR) is characterized by increases in serum IL-6 and the proportion of Th17 cells in circulating blood. During PMR, IL-6 may originate…
Abstract Number: 1224 • ACR Convergence 2025
Comparative Effectiveness of Duloxetine versus Pregabalin in Fibromyalgia: A Large-Scale, Real-World Study Across 300,000 Patients
Chukwuemelie Okeke¹, Queeneth Edwards², Ufuoma Mamoh³, Justin Riley Lam⁴ and Chekwubejah Uwakwe⁵, ¹Maimonides Medical Center, Brooklyn, NY, ²Department of Epidemiology and Biostatistics, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, GA, ³Medstar Health Georgetown University Internal Medicine Residency Program, Baltimore, MD, ⁴Jefferson Einstein Hospital, Philadelphia, PA, ⁵Nnamdi Azikiwe University Teaching Hospital, Nigeria, Nnewi, Anambra, Nigeria
Background/Purpose: Fibromyalgia (FM) is a chronic, debilitating condition characterized by widespread pain, fatigue, and cognitive disturbances. Despite the availability of FDA-approved treatments, real-world comparative effectiveness…
Abstract Number: 1137 • ACR Convergence 2025
Increased Risk of Cardiovascular Events and Mortality Related to Diffuse Idiopathic Skeletal Hyperostosis (DISH): A Systematic Review and Meta-Analysis
Pitchaporn Yingchoncharoen¹, Nattanicha Chaisrimaneepan², Miriam Paz³, Chanokporn Puchongmart¹, Ben thiravetyan¹, Panat Yanpiset¹ and Jerapas Thongpiya⁴, ¹Texas Tech Health Sciences Center, Lubbock, TX, ²Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ³Texas Tech University Health Sciences Center, Lubbock, ⁴Texas Tech University Health Sciences Center at Lubbock Program, Lubbock, TX
Background/Purpose: Diffuse Idiopathic Skeletal Hyperostosis (DISH) is characterized by ossification and calcification of the entheses with prevalence increasing with age. It has been reported to…
Abstract Number: 1236 • ACR Convergence 2025
Vestibulocortical Stimulation via Caloric Irrigation in Nociplastic Disease: Therapeutic Effects on Pain, Autonomic Functioning & Quality of Life Measures
Michael Kaplan¹, Alexandra Canori², Rebecca Howard², Talia Torkian³, Rebecca Pietro¹, Gabriela Santiago-Pichardo¹, Daniel Clauw⁴, David Putrino², Yousaf Ali¹, Laura Tabacof² and Trung Ngo⁵, ¹Division of Rheumatology, Mount Sinai Hospital, New York, ²Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, ³Division of Rheumatology, Icahn School of Medicine at Mount sinai, New York, ⁴Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ⁵RECOVER Injury Research Centre, The University of Queensland and Surgical, Treatment & Rehabilitation Service (STARS), Queensland, Australia
Background/Purpose: Fibromyalgia (FM) and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are prototypical nociplastic disorders marked by centralized pain & fatigue, respectively. Nociplastic symptoms — such as…
Abstract Number: 1000 • ACR Convergence 2025
A Deep-Learning Based Approach Uncovers Novel Mediators of Micro-RNA Restraint of Type-2 Immunity
Shaan Sekhon¹, Robin Kageyama², Neil Sprenkle³, Hannah Happ², Eric Wigton², Heather Pua³ and Mark Ansel², ¹University of California, San Francisco, Berkeley, ²University of California, San Francisco, San Francisco, ³Vanderbilt University, Nashville
Background/Purpose: MicroRNAs, such as miR-24 and miR-27, co-expressed within the Mirc11 and Mirc22 clusters, orchestrate a regulatory network critical to Th2 cell differentiation and cytokine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].